The
blood-brain barrier blocks the development of biologic pharmaceuticals
for brain
ArmaGen provides
platform technology solutions to the 'blood-brain barrier' problem,
and can non-invasively target recombinant proteins, therapeutic
monoclonal antibodies, and siRNA to the brain
|
Brain
blood vessels form the blood-brain barrier and block drug access
to the brain
|
| News
April 10, 2009 |
ArmaGen
plans First in Human clinical trial
cGMP
Manufacturing. ArmaGen’s
lead therapeutic is a genetically engineered
fusion protein of a neurotrophin
and an engineered monoclonal antibody. The
antibody crosses the human blood-brain barrier
(BBB) and acts as a molecular Trojan horse
to carry into brain the attached neuroprotective
neurotrophin. In preparation.....
|
|
|
